Ionis to Host Fourth Quarter and Full Year 2024 Financial Results Webcast

Ionis Pharmaceuticals, Inc. (IONS) is gearing up to host a webcast on Wednesday, February 19, 2025, at 11:30 a.m. Eastern Time, to discuss its fourth quarter and full year 2024 financial results. The webcast will be accessible through the company's investor relations website, and a replay will be available for a limited time afterward. This event is an opportunity for investors and stakeholders to gain insights into Ionis' financial performance and strategic direction for the year.

In the third quarter of 2024, Ionis reported total revenue of $134 million, a 7% decrease compared to the same period last year. However, the company's nine-month revenue increased by 3% to $479 million, driven by new royalty revenue from the launch of WAINUA in the U.S. in the first quarter. Ionis' operating expenses increased as planned, reflecting continued investments in late-stage development and commercialization efforts for WAINUA, olezarsen, and donidalorsen.



Ionis' strong cash position, bolstered by a recent $500 million equity offering, provides runway for growth and supports its pipeline development and commercialization efforts. The company's pipeline shows significant commercial potential with multiple near-term catalysts, including two key regulatory decisions approaching: olezarsen for FCS (PDUFA date December 19, 2024) and donidalorsen for HAE (PDUFA date August 21, 2025).

Investors and stakeholders can expect Ionis' management team to provide updates on the company's financial performance, pipeline progress, and strategic initiatives during the webcast. The company's recent achievements, combined with its advancing and expanding pipeline, position Ionis to deliver on its goal of bringing a steady cadence of transformational medicines to people with serious diseases.



In conclusion, Ionis Pharmaceuticals' fourth quarter and full year 2024 financial results webcast is an essential event for investors and stakeholders to stay informed about the company's financial performance and strategic direction. With a strong pipeline, robust cash position, and a commitment to delivering transformational medicines, Ionis is well-positioned to continue its growth and success in the market.